A Novel Scoring System Based on the Level of HDL-C for Predicting the Prognosis of t-DLBCL Patients: A Single Retrospective Study

Table 2

Response to treatment of the t-DLBCL patients.

Treatment/Response, n ()	Total patients	/DLBCL	/DLBCL	Others/DLBCL	P value
	N=46	N=25	N=15	N=6
Not treated	3	1	2	0
Induction therapy	43	24	13	6
based	32 (74.4)	17 (70.8)	11 (84.6)	4 (66.7)
Chemotherapy without R	10 (23.3)	6 (25.0)	2 (15.4)	2 (33.3)	NS
Radiotherapy only	1 (2.3)	1 (4.2)	0 (0.0)	0 (0.0)
Response to initial treatment
	4 (10.5)	3 (15.0)	1 (8.3)	0 (0.0)	NS
	25 (65.8)	11 (55.0)	10 (83.3)	4 (66.7)	NS
	29 (76.3)	14 (70.0)	11 (91.7)	4 (66.7)	NS
	9 (23.7)	6 (30.0)	1 (8.3)	2 (33.3)	NS
	5	4	1	0
Survival
Estimated median , years	NR	NR	NR
Estimated median , years	4.364	4.301	5.950

R, rituximab; OS, overall survival; PFS, progression free survival; CR, complete remission; PR, partial remission; OR, overall response; NA, not available; NR, not reached; NS, not significant.
Details in the OS of the 6 patients: (1) 1.114 years, alive; (2) 0.194 years, dead; (3) 1.592 years, dead; (4) 4.772 years, alive; (5) 1.444 years, alive; (6) 0.372 years, dead.
Details in the PFS of the 6 patients: (1) 1.114 years, PR; (2) 0.194 years, dead; (3) 1.028 years, PD; (4) 0.675 years, PD; (5) 1.444 years, PR; (6) 0.303 years, PD.